MOTS-c vs Survodutide
A side-by-side research comparison of MOTS-c and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MOTS-c | Survodutide |
|---|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 2,175 Da | 4,500 Da (approximate) |
| Half-life | 4-8 hours | 5-7 days |
| Bioavailability | Moderate (SubQ) | High (SubQ) |
| Typical dose | 5-10 mg | 0.6-6.0 mg |
| Frequency | 3-5x per week | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.